James Stoever, DO
Endocrinology, Diabetes & Metabolism · Savannah, GANPI 1679515894
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (34.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Merck at 36.7% of the total. Reporting peaked in 2019 at $8,682 and has fallen 98.9% since, to $96 in 2025.
Across 191 payments — averaging $56.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- Corcept Therapeutics$4K
- Boehringer Ingelheim$494
- AstraZeneca$398
- Lilly USA, LLC$375
- Dexcom, Inc.$292
- plus $1K from 22 others
What the payments were for
- Consulting fees$2,25021%
- Speaking & faculty fees$3,64034%
- Travel & lodging$1,23311%
- Food & beverage$3,70734%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 13 | $3,971 |
| Corcept Therapeutics | 8 | $3,872 |
| Boehringer Ingelheim | 27 | $494 |
| AstraZeneca(2 entities) | 27 | $398 |
| Lilly USA, LLC | 25 | $375 |
| Dexcom, Inc. | 13 | $292 |
| Novo Nordisk | 16 | $255 |
| Insulet Corporation | 7 | $230 |
| AbbVie | 7 | $111 |
| BD | 6 | $99 |
| Medtronic(2 entities) | 5 | $98 |
| Amgen | 6 | $89 |
| IBSA Pharma Inc. | 5 | $85 |
| Radius Health, Inc. | 5 | $78 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Antares Pharma, Inc. | 3 | $43 |
| Amarin Pharma, Inc. | 2 | $42 |
| BETA Bionics, Inc. | 1 | $39 |
| Johnson & Johnson | 2 | $32 |
| Tandem Diabetes Care, Inc. | 1 | $29 |
| Mannkind Corporation | 2 | $28 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Shire North American Group Inc | 1 | $16 |
| Lifescan, Inc. | 1 | $14 |
| Abbott | 1 | $13 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,830 in reported general payments places this provider in the 80th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 14 | $592,315 |
| MounjaroTirzepatide | 334 | $410,403 |
| TrulicityDulaglutide | 231 | $292,786 |
| OzempicSemaglutide | 223 | $268,543 |
| JardianceEmpagliflozin | 289 | $254,222 |
| FarxigaDapagliflozin Propanediol | 301 | $233,967 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 95 | $116,940 |
| Tresiba Flextouch U-200Insulin Degludec | 87 | $98,629 |
| Tresiba Flextouch U-100Insulin Degludec | 148 | $83,997 |
| RybelsusSemaglutide | 63 | $83,610 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 43 | $69,854 |
| Novolog FlexpenInsulin Aspart | 219 | $63,748 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $62,571 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 367 | $62,273 |
| Humalog Kwikpen U-100Insulin Lispro | 147 | $56,592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $375 | $715,952604 claims |
| Corcept TherapeuticsKorlym | $3,872 | $592,31514 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $255 | $384,553383 claims |
| Boehringer IngelheimJardiance, Tradjenta | $494 | $280,109333 claims |
| AstraZenecaFarxiga | $398 | $233,967301 claims |
| MerckJanuvia, Janumet, Janumet Xr | $3,971 | $89,791103 claims |
| AbbVieSynthroid | $111 | $52,582604 claims |
| Johnson & JohnsonInvokana | $32 | $35,82443 claims |
| AmgenProlia | $89 | $19,08211 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $52 | $11,37812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Savannah
- Ismary DecastroSavannah$169K
- Kaveh EhsanipoorSavannah$76K
- Joseph DehavenSavannah$58K
- Carolyn NelsonSavannah$25K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.